Mass General Hospital

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Prostate cancer3 trials
• Gastric and oesophageal cancer2 trials
• Liver and biliary tract cancer2 trials
• Lung cancer2 trials
• Pancreatic cancer2 trials
• Alzheimer disease1 trial
• Atrial fibrillation1 trial
• Childhood cancers1 trial
• Colorectal cancer1 trial
• Friedreich ataxia1 trial
• Gout1 trial
• Lewy body dementia1 trial
• and 2 more

Phase

• Phase 13 trials
• Phase 1/22 trials
• Phase 32 trials
• Phase 21 trial
• Phase 41 trial

Status

• Recruiting6 trials
• Active, not recruiting4 trials
• Completed1 trial
• Not yet recruiting1 trial

Lead sponsor

• Novartis Pharmaceuticals3 trials
• CND Life Sciences1 trial
• Emalex Biosciences Inc.1 trial
• Hummingbird Diagnostics1 trial
• I-Mab Biopharma US Limited1 trial
• and 5 more

Running trials

• Not yet recruiting

  IKS04 Regimen in Advanced Solid Tumors That Express CA242

  NCT07738939· Phase 1· Iksuda Therapeutics Ltd.· Source

  Contact: Leon Pappas, MD (principal investigator)

• Recruiting

  A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

  NCT07570979· Phase 1· Novartis Pharmaceuticals· Source

  Contact: Nadia Kelley

• Recruiting

  Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares

  NCT07346079· Phase 4· Massachusetts General Hospital· Source

  Contact: Ana D Fernandes, MA

• Recruiting

  An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

  NCT07206056· Phase 1/2· Novartis Pharmaceuticals· Source

  Contact: Manda Ngin

• Active, not recruiting

  An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

  NCT06991556· Phase 2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung

  NCT05987189· Hummingbird Diagnostics· Source

• Active, not recruiting

  A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

  NCT06021522· Phase 3· Emalex Biosciences Inc.· Source

• Recruiting

  The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

  NCT05836987· Phase 3· Johns Hopkins University· Source

  Contact: Kristen Steinmetz

• Active, not recruiting

  A Diagnostic Test for Dementia With Lewy Bodies

  NCT05479552· CND Life Sciences· Source

• Recruiting

  A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

  NCT05118789· Phase 1/2· Nuvalent Inc.· Source

  Contact: Jessica Lin, MD (principal investigator)

• Recruiting

  Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

  NCT04900818· Phase 1· I-Mab Biopharma US Limited· Source

  Contact: Clinical Development

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Gastric and oesophageal cancer2 recruiting
• Liver and biliary tract cancer2 recruiting
• Pancreatic cancer2 recruiting
• Prostate cancer2 recruiting
• Atrial fibrillation1 recruiting
• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Gout1 recruiting
• Lung cancer1 recruiting
• Stroke1 recruiting

Closed trials

• Completed

  Instrumented Data Exchange for Ataxia Study

  NCT04268147· University of Chicago· Source